Founded with a mission to develop novel anti-inflammatory compounds, Function Therapeutics focuses on altering Protease-Activated Receptor signaling (PARmodulins) to treat various inflammatory conditions. Their core vision is to revolutionize the treatment of inflammatory diseases through innovative therapeutic solutions. The company targets markets related to acute kidney injury (AKI), sickle cell disease, and other inflammation-related conditions.
Notable achievements include receiving multiple Phase 1 SBIR Awards from the NIH and NSF, as well as a business development award from the Wisconsin CTC. These accolades underscore the company's scientific and commercial potential. Function Therapeutics has made significant strides in demonstrating the protective effects of parmodulins in preclinical models, positioning itself as a promising player in the field of anti-inflammatory therapeutics.
